2023 Financial Guidance: PTC anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion. PTC anticipates net product revenues for the DMD franchise for the full year 2023 to be between $545 and $565 million. PTC anticipates GAAP R&D and SG&A expense for the full year 2023 to be between $1.01 and $1.06 billion. PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2023 to be between $890 and $940 million, excluding estimated non-cash, stock-based compensation expense of $120 million. PTC anticipates up to $80 million of one-time payments upon achievement of potential clinical and regulatory success-based milestones from previous acquisitions.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTCT:
